Inito is upgrading test kits.
What’s happening: The fertility startup raised $29M to scale its at-home diagnostics platform.
On track. Inito’s urine-based strips measure all four key hormones related to ovulation, using AI to identify hormone patterns, predict fertile windows, and support conception.
With ~$45M in total funding, it’s now developing AI-engineered antibodies to improve test sensitivity and accuracy, with aims to create a full-spectrum hormone health platform spanning pregnancy, menopause, and life-stage care.
Baby steps. Autonomous fertility care is in demand. Adapting to modern families, Mira and Oova are using hormonal data to improve outcomes at home, while Hertility’s GYN-AI diagnostic tool offers precision insights into fertility-related and gynecological conditions.
Beyond conception, Carrot Fertility is integrating CGMs, Maven Clinic leverages population health insights, and Hormona is scaling at-home hormone tests.
Punchline: Building on preexisting datasets, specialized at-home platforms like Inito and others have potential to become diagnostic powerhouses, creating a DIY tier of the bloodwork arms race.
